Evolving systemic management of urothelial cancers
Wei Shen Tan1, Mae-Yen Tan2, Omar Alhalabi3
1Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Systemic treatments for bladder cancer are advancing beyond chemotherapy. New therapies like immune checkpoint inhibitors and targeted drugs are improving outcomes, with biomarkers guiding personalized treatment approaches.
Area of Science:
- Oncology
- Urology
- Immunotherapy
Background:
- Bladder cancer is a significant global health concern, ranking as the 12th most common cancer worldwide.
- Traditional systemic management for urothelial carcinoma has relied heavily on platinum-based chemotherapy.
Conclusions:
- Novel therapeutic strategies are enhancing outcomes for bladder cancer patients.
- A personalized treatment approach, supported by validated biomarkers, is crucial for predicting treatment response.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:16Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
Published on: May 5, 2022
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi V: Nursing Management
Urinary Tract Infection IV: Nursing Management
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
